跳至主要内容
临床试验/NCT00059449
NCT00059449已完成不适用

Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)3 个研究点 分布在 1 个国家目标入组 372 人开始时间: 2003年4月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
372
试验地点
3

研究概览

简要总结

Necrotizing enterocolitis (NEC) is a serious gastrointestinal disorder that primarily affects preterm infants. About 10% of babies less than 32 weeks gestation at birth will develop it. Overall, 30% of babies who develop NEC will die from it, with many others developing long term gastrointestinal problems. The most important factor in its development is a premature intestinal tract. Epidermal growth factor (EGF) is an important growth factor in the development and maintenance of the gastrointestinal tract. This study will look for a relationship between EGF levels in premature babies and the development of NEC.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
— 至 72 Hours(Child)
性别
All
接受健康志愿者

入选标准

  • Gestational Age greater than 23 weeks at birth
  • Birth weight greater than 500 grams
  • Age less than 72 hours of life

排除标准

  • 未提供

研究者

研究点 (3)

Loading locations...

相似试验